CN108018302A - A kind of screening technique of high expression foreign protein stable cell line - Google Patents
A kind of screening technique of high expression foreign protein stable cell line Download PDFInfo
- Publication number
- CN108018302A CN108018302A CN201610928023.8A CN201610928023A CN108018302A CN 108018302 A CN108018302 A CN 108018302A CN 201610928023 A CN201610928023 A CN 201610928023A CN 108018302 A CN108018302 A CN 108018302A
- Authority
- CN
- China
- Prior art keywords
- foreign protein
- cell line
- stable cell
- high expression
- screening technique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Abstract
The invention belongs to biological technical field, more specifically, the invention discloses a kind of screening technique of the stable cell line of high expression foreign protein, comprise the following steps：(a) using Cycle Regulation agent processing cell；(b) recombinant plasmid comprising foreign protein is imported to the cell handled through the Cycle Regulation agent；(c) stable cell line of the high expression foreign protein of screening.The method of the present invention can be efficiently used for screening the stable cell line of high expression foreign protein, and easy to operate, of low cost, it is not necessary to which that additional detections foreign protein, has extensive prospects for commercial application.
Description
Technical field
The invention belongs to biological technical field, and in particular to a kind of screening side of the stable cell line of high expression foreign protein
Method.
Background technology
Gene recombination technology is extensive in recombinant protein pharmaceutical field development and application, has with the albumen of mammalian cell expression
Have and be similar to the protein modified of human body itself.The technology into host cell, passes through the plasmid transfection of carrying target gene
After multi-turns screen, stable cell line is obtained, stablizes express express target protein, this can guarantee that production in large-scale industrial production
Uniformity, and the uniformity of product.But the expression of current mammalian cell is low, the screening consumption of stable cell line is obtained
Duration, causes production cost high, is the limiting factor in recombinant protein industrialization.
In order to obtain the steady production cell line of high unicellular yield, people use various ways method, including optimization table
Up to carrier, engineered cells etc..Yuan Wumei etc. improved using 1 gene of enhancer SP163- λ recombinant interferon expression (Yuan Wumei,
Numb powder lotus, Zhang Qian, wait interferon lambdas 1 in Chinese hamster ovary celI expression [J] China experiment and clinical virology magazine, 2013,27
(3)：190-192), high aim etc. is carried out by integrating Igf1/Bcl-2 or Bcl-2/Cyclin E gene regulation cell growth states
(carry out high aim, Weng Shaojie, Qi Lianquan, wait to express Igf1/Bcl-2 or Bcl-2/Cyclin E bases by height to improve cell yield
Because combination makes Chinese hamster ovary celI be suitable for anti-apoptotic culture [J] bioengineering journals, 2004,20 (1) in protein-free medium：66-
72)。
But the above method needs to build expression plasmid from the beginning, and/or the screening again of host cell, operation
Complexity, takes longer, it is often more important that, it is also necessary to the foreign protein being thereby introduced into final products is verified in detail, with
Whether guarantee can be with safety applications to pharmaceutical production.Therefore, it is necessary to provide a kind of safe height easy to operate, of low cost
Express the screening technique of foreign protein stable cell line.
The content of the invention
The present invention relates to a kind of screening technique of the stable cell line of high expression foreign protein.Specifically, this method profit
When the cell colony is in the G2/M phases with Cycle Regulation agent, stable transfection, the positive cell obtained after stable transfection are carried out
Rate is high, and cellular expression levels improve, and can effectively improve the screening efficiency of the stable cell line of high expression foreign protein.
Therefore, it is an object of the invention to provide a kind of screening technique of the stable cell line of high expression foreign protein.
To achieve these goals, technical scheme is as follows：
A kind of screening technique of the stable cell line of high expression foreign protein, wherein, comprise the following steps：
(a) using Cycle Regulation agent processing cell；
(b) (a) will be imported comprising the recombinant plasmid of exogenous protein expression gene to handle through the Cycle Regulation agent
In cell；
(c) stable cell line of the high expression foreign protein of screening.
The Cycle Regulation agent that the present invention uses can make the cell be in G2/M phases, such as aphidicolin
(aphidicolin), MDK inhibitor Roscovitine.Preferably, the Cycle Regulation agent is aphidicolin.It is preferred that
, the activity of the aphidicolin is 0-2 μ g/ml (not including 0 μ g/ml and 2 μ g/ml).It is furthermore preferred that the A Fei
The activity of enlightening mycin is 0.5-1 μ g/ml.Preferably, when the action time of the aphidicolin is 4-24 small.More preferably
, when the action time of the aphidicolin is 8 small.
The cell that the present invention uses is mammalian cell, including Chinese hamster ovary celI, 293 cells, suitable for expressing purpose external source
Albumen.Preferably, the mammalian cell is Chinese hamster ovary celI.It is furthermore preferred that the Chinese hamster ovary celI is CHO-S or DG44.
Heretofore described foreign protein may include antibody, fusion protein, cell factor, be preferably antibody.It is furthermore preferred that
The antibody is anti-GPNMB antibody.
Electroporation transfection method or polyetherimide (PEI) infection protocol can be selected in the method for the importing that the present invention uses.
Beneficial effect：Present invention discover that the cell after aphidicolin is handled, which adds foreign gene, carries out stable transfection
Afterwards, and conventional group without Cycle Regulation agent processing is compared screening gained highest exogenous protein expression amount, the results show Ah
The exogenous protein expression amount of the stable cell line of screening gained substantially increases after non-enlightening mycin processing.Therefore, method of the invention
It can be efficiently used for screening the stable cell line of high expression foreign protein, and it is easy to operate, it is of low cost, it is not necessary to extra
Foreign protein is detected, there is extensive prospects for commercial application.
Brief description of the drawings
Fig. 1 is after the cell after pCGS-GFP transfections spreads semisolid culturemedium, to be given birth to the cell clone of Clonepix scannings
Long situation, wherein, (a) and (b) figure are normal control cells, and (c) and (d) figure are aphidicolin treatment groups：(a) in holes
Cell is normal control hole, and upper figure is cell fluorescence intensity-cell arrangement figure in (b), and figure below is cell quantity-cell fluorescence
Intensity map, holes handles hole for aphidicolin in (c), and upper figure is cell fluorescence intensity-cell arrangement figure in (d), and figure below is
Cell quantity-cell fluorescence intensity figure.
Fig. 2 is after the cell after the anti-GPNMB antibody transfections of pCGS- spreads semisolid culturemedium, to be scanned with Clonepix thin
Born of the same parents' clonal growth situation, wherein, (a) and (b) figure are normal control cells, and (c) and (d) figure are aphidicolin treatment groups：(a)
Cell is normal control hole in middle holes, and upper figure is cell fluorescence intensity-cell arrangement figure in (b), figure below be cell quantity-
Cell fluorescence intensity figure, holes handles hole for aphidicolin in (c), and upper figure is cell fluorescence intensity-cell arrangement in (d)
Figure, figure below is cell quantity-cell fluorescence intensity figure.
Fig. 3 is that the expression quantity in 96 orifice plates that is cloned in that 96 orifice plate limiting dilutions obtain compares, wherein, (a) is normal control
Group, (b) are aphidicolin treatment group.
Embodiment
Following embodiments, experimental example are that the present invention is further detailed.
Influence of one cell cycle inhibitor of embodiment under different pharmaceutical concentration and action time to cell
0th day, (derived from Fusion culture mediums (deriving from Sigma) the dilution CHOZN cells containing glutamine
Sigma), spread to 24 orifice plates, per hole cell density 0.5 × 106/ ml, is divided into 5 groups, is separately added into 0,0.5,1,2,4 μ g/ml
Aphidicolin, sample and count when the 4th, 8,20 is small, vitro growth rates and the cell for comparing different time points be straight
Footpath changes, and reflects change (be shown in Table 1) of the permeability of cell under different pharmaceutical concentration and action time.The results show that medicine
Act on 4 it is small when i.e. visible cell growth inhibition, 8 it is small when effect after remove medicine, can recover to normal growth, 8 hour cells are straight
Footpath change is obvious, wherein 2 μ g/ml and 4 μ g/ml effects visible cell diameter change is most obvious, but the two concentration versus cells are given birth to
With irreversible influence, even if removing medicine, cell growth cannot be recovered, and 4 μ g/ml groups under all different action times not
See that cell increases, it is therefore proposed that it is 0-2 μ g/ml (not including 0 μ g/ml and 2 μ g/ml) to recommend drug concentration, preferred concentration is 1 μ
g/ml。
The influence of table 1, different pharmaceutical action time and drug concentration cell growth and cell dia
Two foreign protein of embodiment detects for the expression quantity of green fluorescent protein (GFP)
To three groups of cells (CHOZN, from Sigma) respectively with electroporation transfection and PEI methods transfection band GFP plasmids
(pCGS-GFP, pCGS plasmid origin are in Sigma)：1. normal untreated cell group；2. normal untreated cell：Aphidicolin
1 μ g/ml handle 24 hour cells (1：1) mixing group；Group when 3. 1 μ g/ml of aphidicolin processing 24 is small.24 it is small when after in fluorescence
The positive rate (transfection efficiency) with fluorecyte is counted with blood counting chamber under microscope, and cell is detected with stream type cell analyzer
Transfection efficiency (is compareed) with non-transfected cells, 1. 2. 3. analysis, which is compared, organizes transfection positive rate (being shown in Table 2 and table 3), blood counting chamber
Count and flow cytometry analysis is the results show that with the cell increase of drug-treated in the cell colony of transfection, its is final
The fluorescent positive rate increase of acquisition, illustrates that the medicine can promote plasmid transfection efficiency.
Cell paving semisolid culturemedium (article No. 1. will be 3. organized at the same time：K8742, from MD) in, treat cell clonal formation
Afterwards, clone's fluorescence intensity is scanned with Clonepix, compares the monoclonal fluorescence intensity to be formed.Although Clonepix results illustrate just
The cell clone of normal control group growth is more, but the clone for having highest fluorescence intensity then appears in administration group (see Fig. 1), up to
8000, and normal control only 6000.
Table 2, the transfection efficiency of different cell colonys compare (blood counting chamber counting)
Table 3, the transfection efficiency of different cell colonys compare (flow cytometry analysis)
Three foreign protein of embodiment detects for the expression quantity of antibody
With the plasmid of electroporation transfection expression antibody, (the anti-GPNMB antibody of pCGS-, pCGS plasmids come two groups of cells respectively
Sigma is come from, GPNMB antibody is prepared according to method described in patent document WO2006/071441)：It is 1. normal untreated
Groups of cells；Group when 2. 1 μ g/ml of aphidicolin processing 24 is small.24 it is small when after two groups of cells are spread in semisolid culturemediums, treat thin
After born of the same parents' Clone formation, clone's fluorescence intensity is scanned with Clonepix, compares the monoclonal fluorescence intensity to be formed, sees Fig. 2.As a result say
Bright Normal group acquisition clone is more, but mostly low expression cell clone, and highest fluorescence intensity is only 4400, and corresponding administration
The most hyperfluorescence intensity of group is 6600.
After cell pressurization screening after transfection, with 96 orifice plates of limiting dilution assay point, after cell clone grows out, supernatant is used
Fortebio detects its expression quantity, and the result is shown in Fig. 3, the clonal expression amount that Normal group obtains is mostly 0-10 μ g/ml, and only one
A is 10.7ug/ml, and the clonal expression of corresponding aphidicolin group is up to 25.1 μ g/ml, and the clone more than 10 μ g/ml
There are 7, hence it is evident that the high-expression clone of visible administration group is more, and then the highest clone of 96 orifice plate expression quantity in two groups is picked out
Amplification, carries out the sugared batch cultivation assessment of simple benefit in 125ml shaking flasks, and supernatant detects its expression quantity with Fortebio, derives from
The final expression quantity of clone of aphidicolin group is 920mg/l, and the clonal expression amount of corresponding Normal group is 770mg/
l.These results suggest that the method for the present invention can effectively improve the screening efficiency of the stable cell line of high expression foreign protein,
And it is easy to operate, it is of low cost, it is not necessary to which that additional detections foreign protein, has extensive prospects for commercial application.
Claims (10)
1. a kind of screening technique of the stable cell line of high expression foreign protein, it is characterised in that comprise the following steps：
(a) using Cycle Regulation agent processing cell；
(b) cell that will be handled comprising the recombinant plasmid of exogenous protein expression gene importing (a) through the Cycle Regulation agent
In；
(c) stable cell line of the high expression foreign protein of screening.
2. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 1, it is characterised in that described thin
Born of the same parents' periodic adjustment agent makes the cell be in the G2/M phases.
3. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 2, it is characterised in that described thin
The agent of born of the same parents' periodic adjustment is aphidicolin, MDK inhibitor, it is preferred that the Cycle Regulation agent is aphidicolin.
4. the screening technique of the stable cell line of expression foreign protein as claimed in claim 3 high, it is characterised in that Ah
The activity of non-enlightening mycin is 0-2 μ g/ml (not including 0 μ g/ml and 2 μ g/ml), it is preferred that the work of the aphidicolin
It is 0.5-1 μ g/ml with concentration.
5. the screening technique of the stable cell line of expression foreign protein as claimed in claim 3 high, it is characterised in that Ah
When the action time of non-enlightening mycin is 4-24 small, it is preferred that when the action time of the aphidicolin is 8 small.
6. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 1, it is characterised in that described thin
Born of the same parents are mammalian cell.
7. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 6, it is characterised in that the food in one's mouth
Newborn zooblast is Chinese hamster ovary celI, 293 cells, it is preferred that the mammalian cell is Chinese hamster ovary celI, it is furthermore preferred that the CHO
Cell is CHO-S or DG44.
8. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 1, it is characterised in that described outer
Source protein is antibody, fusion protein, cell factor, it is preferred that the foreign protein is antibody.
9. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 8, it is characterised in that described anti-
Body is anti-GPNMB antibody.
10. the screening technique of the stable cell line of high expression foreign protein as claimed in claim 1, it is characterised in that described
The method of importing is electroporation transfection method or PEI infection protocols.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610928023.8A CN108018302A (en) | 2016-10-31 | 2016-10-31 | A kind of screening technique of high expression foreign protein stable cell line |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610928023.8A CN108018302A (en) | 2016-10-31 | 2016-10-31 | A kind of screening technique of high expression foreign protein stable cell line |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108018302A true CN108018302A (en) | 2018-05-11 |
Family
ID=62070299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610928023.8A Pending CN108018302A (en) | 2016-10-31 | 2016-10-31 | A kind of screening technique of high expression foreign protein stable cell line |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108018302A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111598029A (en) * | 2020-05-21 | 2020-08-28 | 东莞太力生物工程有限公司 | Method, system, server and storage medium for screening target cell strain |
| RU2768735C1 (en) * | 2020-12-31 | 2022-03-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) | Method of producing stable recombinant protein producer cell line |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106029691A (en) * | 2013-12-20 | 2016-10-12 | 诺华股份有限公司 | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
-
2016
- 2016-10-31 CN CN201610928023.8A patent/CN108018302A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106029691A (en) * | 2013-12-20 | 2016-10-12 | 诺华股份有限公司 | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
Non-Patent Citations (2)
| Title |
|---|
| JANET H. PARHAM ET AL: "Optimization of transient gene expression in mammalian cells and potential for scale-up using flow electroporation", 《CYTOTECHNOLOGY》 * |
| 李春艳等: "流式细胞仪分选非染色S期CHO细胞有助于提高聚乙烯亚胺的转染效率", 《解剖科学进展》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111598029A (en) * | 2020-05-21 | 2020-08-28 | 东莞太力生物工程有限公司 | Method, system, server and storage medium for screening target cell strain |
| RU2768735C1 (en) * | 2020-12-31 | 2022-03-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) | Method of producing stable recombinant protein producer cell line |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dulbecco | Transformation of Cells in vitro by Viruses: Investigation of such transformations provides an experimental approach to the study of cancer. | |
| CN105950544B (en) | Domestication method of full suspension culture type Marc-145 cell line | |
| CN102634482B (en) | Serum-free complete medium for mesenchymal stem cell | |
| CN104805054A (en) | Serum-free medium of stem cell | |
| CN102653725B (en) | Bacillus coagulans and application thereof in mixed fermentation to produce L-lactic acid | |
| CN102321587A (en) | Construction of lung cancer drug screening cell line | |
| CN108004202B (en) | Culture solution for serum-free suspension culture of 293T cells | |
| CN106609263B (en) | Method for efficiently inducing differentiation of pluripotent stem cells to retinal pigment epithelial cells | |
| CN105112363B (en) | A kind of serum free medium of human adipose mesenchymal stem cells and preparation method thereof | |
| CN105112365A (en) | Serum-free medium for human umbilical cord mesenchymal stem cells and preparation method thereof | |
| CN105112352A (en) | ST cell adapting to full-suspension culture, and application thereof, and vaccine virus culturing method | |
| CN103205396A (en) | Suspension acclimatization and serum-free acclimatization method for HEK (human embryonic kidney)-293T cells | |
| CN107338220A (en) | The method and its culture medium that inductive pluripotent stem cells break up to candidate stem cell | |
| CN108018302A (en) | A kind of screening technique of high expression foreign protein stable cell line | |
| CN102653724A (en) | Lactobacillus casei and application thereof to produce L-lactic acid by fermentation | |
| CN109913404A (en) | The preparation method of infections chicken cloacal bursa virus live vaccine | |
| CN103012590B (en) | Anti-CD20 monoclonal antibody, preparation method and application thereof | |
| CN102191215A (en) | Human-derived serum-free culture medium and preparation method thereof | |
| CN101831403A (en) | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro | |
| CN107099495A (en) | A kind of construction method and application that engineered strain is delivered for mammalian cell protein matter | |
| CN101497865A (en) | Yeast strain for producing low diacetyl beer | |
| CN104894054A (en) | Monkey embryo renal epithelial cell Marc-145 suspension adapted strain and application thereof in culture of PRRSV (porcine reproductive and respiratory syndrome virus) and production of PRRSV vaccine | |
| CN107236763A (en) | A kind of method for building Knockout cells system based on flow cytometry | |
| CN108441481A (en) | A kind of Chimeric antigen receptor T cell and its cultural method | |
| CN101333513B (en) | Non-blood serum low density culture medium for animal cell and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180511 |